YANGI IMMUNOTERAPIYA USULLARI VA SARATON HUJAYRALARINING GENETIK MODIFIKATSIYASI
Keywords:
Immunoterapiya, CAR-T hujayralari, genetik modifikatsiya, saraton, CRISPR/Cas9, neoantigen, hujayraviy terapiya, biotibbiyot, onkologiya.Abstract
Ushbu maqolada zamonaviy onkologiyada saraton kasalliklariga qarshi kurashishning innovatsion yondashuvi sifatida qaralayotgan immunoterapiya usullari va saraton hujayralarining genetik modifikatsiyasi muhokama qilinadi. Ayniqsa, CAR-T (Chimeric Antigen Receptor T-cell) terapiyasi, neoantigen asosidagi vaktsinalar, hamda genetik tahrirlash texnologiyalari, jumladan CRISPR/Cas9 tizimi orqali saraton hujayralarini nishonli modifikatsiya qilish mexanizmlari yoritilgan. Maqolada bu yondashuvlarning klinik amaliyotdagi afzalliklari, xavfsizlik omillari va kelajakdagi rivojlanish istiqbollari ilmiy izohlar bilan tahlil qilinadi.
References
1. June, C.H., Sadelain, M. (2018). Chimeric Antigen Receptor Therapy. New England Journal of Medicine, 379(1), 64–73. doi:10.1056/NEJMra1706169
2. Rosenberg, S.A., Restifo, N.P. (2015). Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 348(6230), 62–68. doi:10.1126/science.aaa4967
3. Farkona, S., Diamandis, E.P., Blasutig, I.M. (2016). Cancer immunotherapy: the beginning of the end of cancer? BMC Medicine, 14(1), 73. doi:10.1186/s12916-016-0623-5
4. Maude, S.L., et al. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439–448.
5. Doudna, J.A., Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096. doi:10.1126/science.1258096
6. Sahin, U., Türeci, Ö. (2018). Personalized vaccines for cancer immunotherapy. Science, 359(6382), 1355–1360. doi:10.1126/science.aar7112
7. Ribas, A., Wolchok, J.D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350–1355. doi:10.1126/science.aar4060
8. National Cancer Institute. (2023). Immunotherapy to Treat Cancer. Retrieved from: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy
9. FDA. (2023). Approved Cellular and Gene Therapy Products. U.S. Food & Drug Administration. https://www.fda.gov
